Moreover, in vitro studies suggested that the overexpression of SPRYD4 impaired S/G2 progression in the cell cycle and promoted cell apoptosis, which inhibited CCA initiation and progression. This evidence concerns the gene SPRYD4 and cholangiocarcinoma.